Our study, which to our knowledge was the first study evaluating the role of DPP4 inhibition on cancers in human subjects, found statistically significant benefit in progression‐free survival and a positive trend in overall survival (OS); however, this benefit in OS did not reach the level of statistical significance, likely due to the relatively small number of subjects included in the study.12 As a follow‐up and to further clarify the role of DPP4 inhibitors in human malignancies, we conducted a national database study in CRC and lung cancer. This evidence concerns the gene DPP4 and cancer.